iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.88 Billion KRW | -94.59% |
| 2022 | 34.77 Billion KRW | -33.14% |
| 2021 | 52.01 Billion KRW | 243.19% |
| 2020 | 15.15 Billion KRW | -36.88% |
| 2019 | 24.01 Billion KRW | 53.44% |
| 2018 | 15.65 Billion KRW | 2.08% |
| 2017 | 15.33 Billion KRW | 51.72% |
| 2016 | 10.1 Billion KRW | 70.47% |
| 2015 | 5.92 Billion KRW | 0.0% |
| 2012 | 7.71 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.87 Billion KRW | -63.57% |
| 2024 Q1 | 5.15 Billion KRW | 174.26% |
| 2023 Q3 | 2.11 Billion KRW | -94.09% |
| 2023 Q1 | 34.64 Billion KRW | -0.38% |
| 2023 FY | 1.88 Billion KRW | -94.59% |
| 2023 Q2 | 35.78 Billion KRW | 3.27% |
| 2023 Q4 | 1.88 Billion KRW | -11.08% |
| 2022 FY | 34.77 Billion KRW | -33.14% |
| 2022 Q4 | 34.77 Billion KRW | 1.07% |
| 2022 Q3 | 34.4 Billion KRW | -1.52% |
| 2022 Q2 | 34.93 Billion KRW | -31.8% |
| 2022 Q1 | 51.22 Billion KRW | -1.52% |
| 2021 Q3 | 50.6 Billion KRW | 397.79% |
| 2021 Q4 | 52.01 Billion KRW | 2.8% |
| 2021 FY | 52.01 Billion KRW | 243.19% |
| 2021 Q1 | 9.57 Billion KRW | -36.84% |
| 2021 Q2 | 10.16 Billion KRW | 6.18% |
| 2020 FY | 15.15 Billion KRW | -36.88% |
| 2020 Q1 | 24.34 Billion KRW | 1.38% |
| 2020 Q4 | 15.15 Billion KRW | -12.76% |
| 2020 Q3 | 17.37 Billion KRW | -35.68% |
| 2020 Q2 | 27 Billion KRW | 10.95% |
| 2019 Q3 | 39.16 Billion KRW | 8.39% |
| 2019 FY | 24.01 Billion KRW | 53.44% |
| 2019 Q1 | 12.37 Billion KRW | -20.94% |
| 2019 Q4 | 24.01 Billion KRW | -38.68% |
| 2019 Q2 | 36.13 Billion KRW | 192.02% |
| 2018 Q4 | 15.65 Billion KRW | -4.09% |
| 2018 FY | 15.65 Billion KRW | 2.08% |
| 2018 Q3 | 16.31 Billion KRW | 23.78% |
| 2018 Q2 | 13.18 Billion KRW | -13.4% |
| 2018 Q1 | 15.22 Billion KRW | -0.71% |
| 2017 Q1 | 9.53 Billion KRW | -8.77% |
| 2017 FY | 15.33 Billion KRW | 51.72% |
| 2017 Q4 | 15.33 Billion KRW | 9.74% |
| 2017 Q3 | 13.97 Billion KRW | -13.01% |
| 2017 Q2 | 16.06 Billion KRW | 68.36% |
| 2016 Q4 | 10.45 Billion KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 FY | 10.1 Billion KRW | 70.47% |
| 2015 FY | 5.92 Billion KRW | 0.0% |
| 2013 Q3 | 5.63 Billion KRW | -2.4% |
| 2013 Q2 | 5.76 Billion KRW | -24.88% |
| 2013 Q1 | 7.68 Billion KRW | -0.46% |
| 2012 FY | 7.71 Billion KRW | 0.0% |
| 2012 Q4 | 7.71 Billion KRW | -20.68% |
| 2012 Q3 | 9.72 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 98.89% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 97.516% |
| Bioneer Corporation | 80.61 Billion KRW | 97.667% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | 90.592% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 98.615% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 98.078% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 97.444% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 99.824% |
| Medy-Tox Inc. | 137.14 Billion KRW | 98.629% |
| Peptron, Inc. | 16.36 Billion KRW | 88.513% |
| Amicogen, Inc. | 248.12 Billion KRW | 99.242% |
| Genexine, Inc. | 79.68 Billion KRW | 97.64% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 93.577% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | 95.445% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 98.263% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 97.427% |
| SillaJen, Inc. | 19.4 Billion KRW | 90.308% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 98.95% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 96.418% |
| Genomictree Inc. | 7.81 Billion KRW | 75.931% |
| MedPacto, Inc. | 9.56 Billion KRW | 80.343% |
| D&D Pharmatech | 23.98 Billion KRW | 92.16% |
| EASY BIO,Inc. | 105.86 Billion KRW | 98.224% |
| GI Innovation, Inc. | 9.63 Billion KRW | 80.486% |